Considering therapy but worried about the cost? If you have insurance, you can check to see if your plan covers therapy services. Read on for more tips on how to find affordable care. Share on ...

They can also help repair or rebuild damaged cells. Medicare covers stem cell therapy for specific uses, mostly for treating certain types of cancer or bleeding disorders, such as sickle cell disease.

Results: Here we show that Tmod cells can be designed to target 2-4 antigens to provide different practical and conceptual options for a blood cancer therapy: (i) mono- and bispecific activating ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...

In a discovery with potential practical applications, a team of Rutgers biophysicists, bioengineers and plant biologists capture first live images In a groundbreaking study on the synthesis of ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. The move isn’t shocking ...

Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting ...

CAR-T cell therapy involves extracting a patient’s T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body. But ...

The CAR-T cell therapy was tested on patients with B-cell leukaemia and lymphoma - rare types of blood cancers - that affect the bone marrow and the lymphatic system. Listen to Story India's first Car ...

I am also a board member of the French Society of Gene and Cell Therapy. I’m looking forward to introducing our ProTcell therapy platform’s recent advances and, more precisely, our efforts to ...

A study published in The Lancet Haematology has reported a 73% response rate for CAR T-cell therapy among patients with certain blood cancers. The clinical trials were conducted by researchers ...